Natalia S. Besova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalia S. Besova has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
11 shared publications - E. S. Obarevich
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Elena V. Artamonova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Liudmila G. Zhukova
Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
6 shared publications - Mikhail Yu. Fedyanin
Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center
6 shared publications - Tatyana A. Titova
N.N. Blokhin National Medical Research Center of Oncology
6 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 116-121
Gastric cancer with bone metastases: Clinical and pathological characteristics
Introduction. Development of bone metastases in gastric cancer are quite rare, and therefore poorly covered in the literature. Aim. To evaluate the clinical and morphological characteristics of patients with metastatic gastric cancer depending on the presence of bone metastases (BM); secondary objectives were to evaluate the long-term results (overall survival, OS) of patient and to assess the incidence of skeletal-related events (SRE) and the effectiveness of using bone modifying agents (BMA). Mat erials and methods. From the register of the MCSC A.S. Loginov 82 patients with gastric cancer bones metastases were selected. For the comparison group, 163 patients with disseminated gastric cancer without bone metastases were selected by pseudorandomization with a 2:1 ratio. The presence of bone metastases in all patients was confirmed by computed tomography (CT) of the thorax, abdomen and pelvis. Results. As a result, groups comparable in basic parameters were formed. Patients with gastric bone metastases were characterized by a younger age, with a higher degree of High-Grade morphology, a greater dissemination of metastases, and a rarer association with peritoneal and liver metastases. According of bone dissemination, the mild burden was noted in 32 (39.0%), moderate in 1 (1.2%), pronounced in 49 (59.8%). When assessing overall survival in the entire group, no differences in OS were shown (12.5 months. and 13.8 months), without statistically significance (HR 0.95; 95% CI 0.9–1.01, p = 0.096), however, at the initial diagnosis of BM, it was lower (11.9 months and 13.8 months, HR 0.94; 95% CI 0.883–0.997; p = 0.039). BMA were used in 38 (46%) patients. At the same time, with severe metastasiс spread to the bones, their use increased OS from 6.7 months to 11.8 months (p = 0.13, HR 0.58; 95% CI 0.29–1.18) and 1-year OS (16% and 45%, p = 0.08, HR 1.58; 95% CI 1.04–2.39). Lytic metastases was detected in 46.1%. SRE in bone metastases was observed in 32.9% of patient, with radiation therapy in 15.9%, pathological fractures in 18.3%, surgical to bone in 3.7%, hypercalcemia in 10.7%. Conclusions. Bone metastases in gastric cancer are quite rare. Their presence does not affect overall survival. The use of OMA in cases of severe skeletal damage contributes to an increase in overall survival.
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 116-121
Open AccessGastric cancer with bone metastases: Clinical and pathological characteristics
Introduction. Development of bone metastases in gastric cancer are quite rare, and therefore poorly covered in the literature. Aim. To evaluate the clinical and morphological characteristics of patients with metastatic gastric cancer depending on the presence of bone metastases (BM); secondary objectives were to evaluate the long-term results (overall survival, OS) of patient and to assess the incidence of skeletal-related events (SRE) and the effectiveness of using bone modifying agents (BMA). Mat erials and methods. From the register of the MCSC A.S. Loginov 82 patients with gastric cancer bones metastases were selected. For the comparison group, 163 patients with disseminated gastric cancer without bone metastases were selected by pseudorandomization with a 2:1 ratio. The presence of bone metastases in all patients was confirmed by computed tomography (CT) of the thorax, abdomen and pelvis. Results. As a result, groups comparable in basic parameters were formed. Patients with gastric bone metastases were characterized by a younger age, with a higher degree of High-Grade morphology, a greater dissemination of metastases, and a rarer association with peritoneal and liver metastases. According of bone dissemination, the mild burden was noted in 32 (39.0%), moderate in 1 (1.2%), pronounced in 49 (59.8%). When assessing overall survival in the entire group, no differences in OS were shown (12.5 months. and 13.8 months), without statistically significance (HR 0.95; 95% CI 0.9–1.01, p = 0.096), however, at the initial diagnosis of BM, it was lower (11.9 months and 13.8 months, HR 0.94; 95% CI 0.883–0.997; p = 0.039). BMA were used in 38 (46%) patients. At the same time, with severe metastasiс spread to the bones, their use increased OS from 6.7 months to 11.8 months (p = 0.13, HR 0.58; 95% CI 0.29–1.18) and 1-year OS (16% and 45%, p = 0.08, HR 1.58; 95% CI 1.04–2.39). Lytic metastases was detected in 46.1%. SRE in bone metastases was observed in 32.9% of patient, with radiation therapy in 15.9%, pathological fractures in 18.3%, surgical to bone in 3.7%, hypercalcemia in 10.7%. Conclusions. Bone metastases in gastric cancer are quite rare. Their presence does not affect overall survival. The use of OMA in cases of severe skeletal damage contributes to an increase in overall survival.
- Open Access
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 33-46
Efficacy of chemoimmunotherapy in first-line treatment of patients with disseminated gastric cancer depending on PD-L1 expression and clinical benefit according to the ESMO-MCBS and RUSSCO criteria: results of a meta-analysis
Background: Addition of anti-PD1 antibodies to chemotherapy (CT) in pts with mGC has become a standard of care. However, there is no consensus on the threshold value of PD-L1 expression in the tumor as a predictor of the effectiveness of this approach (from the opinion that it is possible not to select on expression, to the selection of pts with a CPS ≥ 10). Therefore, we performed systemic review and meta-analysis to evaluate the efficacy of ICT depending on the expression of PD-L1 and compliance with the indicators of clinical benefit in accordance with ESMO-MCBS. Methods: We conducted a search of all prospective randomized phase III studies in PubMed, ASCO and ESMO congresses for all years before June 2023, with anti-PD1 antibodies and CT with oxaliplatin and fluoropyrimidines in 1st line in pts with Her-2 negative mGC. Primary outcome was hazard ratio (HR) for OS and 95 % confidence interval (CI). Fixed or random effects were used for analysis, depending on heterogeneity. Meta-analysis was conducted by Review Manager Ver. 5.3. When calculating the number of points according to ESMO-MCBS, the median OS in the control group was more than 12 months and a point was added for improving the quality of life. Results: We identified 6 trials (ATTRACTION-4, CHECKMATE-649, KEYNOTE-859, ORIENT-16, RATIONALE-305 and GEMSTONE-303), which included 5531 pts (CT — 2762 and ICT — 2769). According to the results of the meta-analysis there was a significant improvement in OS (HR 0.8, 95 % CI 0.75–0.86; p < 0.001; I2 = 0 %, p for heterogeneity 0.74) in groups with ICT in ITT population. Statistically significant improvement in overall survival was observed with PD-L1 CPS expression ≥ 5 (OR 0.71, 95 % CI 0.65–0.78; p < 0.001; I2 = 0 %) with ESMO-MCBS grading level of 3 points and RUSSCO — IC and among patients with PD-L1 CPS expression ≥ 10 (OR 0.65, 95 % CI 0.59–0.71; p < 0.001; I2 = 0 %) and ESMO-MCBS grading level of 4 points and RUSSCO — IB. Conclusions: Addition of anti-PD1 and CT with oxaliplatin and fluoropyrimidines in 1st line in pts with mGC meets the definition of clinical benefit according to the ESMO-MCBS and RUSSCO only by selecting pts with PD-L1 expression CPS ≥ 10.
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 33-46
Open AccessEfficacy of chemoimmunotherapy in first-line treatment of patients with disseminated gastric cancer depending on PD-L1 expression and clinical benefit according to the ESMO-MCBS and RUSSCO criteria: results of a meta-analysis
Background: Addition of anti-PD1 antibodies to chemotherapy (CT) in pts with mGC has become a standard of care. However, there is no consensus on the threshold value of PD-L1 expression in the tumor as a predictor of the effectiveness of this approach (from the opinion that it is possible not to select on expression, to the selection of pts with a CPS ≥ 10). Therefore, we performed systemic review and meta-analysis to evaluate the efficacy of ICT depending on the expression of PD-L1 and compliance with the indicators of clinical benefit in accordance with ESMO-MCBS. Methods: We conducted a search of all prospective randomized phase III studies in PubMed, ASCO and ESMO congresses for all years before June 2023, with anti-PD1 antibodies and CT with oxaliplatin and fluoropyrimidines in 1st line in pts with Her-2 negative mGC. Primary outcome was hazard ratio (HR) for OS and 95 % confidence interval (CI). Fixed or random effects were used for analysis, depending on heterogeneity. Meta-analysis was conducted by Review Manager Ver. 5.3. When calculating the number of points according to ESMO-MCBS, the median OS in the control group was more than 12 months and a point was added for improving the quality of life. Results: We identified 6 trials (ATTRACTION-4, CHECKMATE-649, KEYNOTE-859, ORIENT-16, RATIONALE-305 and GEMSTONE-303), which included 5531 pts (CT — 2762 and ICT — 2769). According to the results of the meta-analysis there was a significant improvement in OS (HR 0.8, 95 % CI 0.75–0.86; p < 0.001; I2 = 0 %, p for heterogeneity 0.74) in groups with ICT in ITT population. Statistically significant improvement in overall survival was observed with PD-L1 CPS expression ≥ 5 (OR 0.71, 95 % CI 0.65–0.78; p < 0.001; I2 = 0 %) with ESMO-MCBS grading level of 3 points and RUSSCO — IC and among patients with PD-L1 CPS expression ≥ 10 (OR 0.65, 95 % CI 0.59–0.71; p < 0.001; I2 = 0 %) and ESMO-MCBS grading level of 4 points and RUSSCO — IB. Conclusions: Addition of anti-PD1 and CT with oxaliplatin and fluoropyrimidines in 1st line in pts with mGC meets the definition of clinical benefit according to the ESMO-MCBS and RUSSCO only by selecting pts with PD-L1 expression CPS ≥ 10.
- 21 January 2026
- Published by Alfmed LLC in Medical alphabet
- No. 33
HER2-positive metastatic gastric / cardioesophageal junction cancer: a comparative retrospective analysis of trastuzumab maintenance therapy regimens
Objective. To evaluate the efficacy and safety of different maintenance therapy regimens in patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Materials and methods. This retrospective analysis included data from 186 patients who received trastuzumab in combination with platinum-fluoropyrimidine chemotherapy. During the maintenance phase, patients were divided into two groups: trastuzumab monotherapy and trastuzumab plus fluoropyrimidines. Results. No significant differences were observed between the groups in overall survival (OS) or progression-free survival (PFS) (OS: 26.0 vs 24.0 months; PFS: 13.5 vs 13.1 months; p>0.05). Combination therapy was associated with a higher incidence of toxicity, including hand–foot syndrome (19.4 % vs 0.8 %) and cardiotoxicity (11.3 % vs 3.2 %). Conclusion. The continuation of fluoropyrimidines during the maintenance phase does not improve treatment efficacy and increases toxicity. The optimal strategy remains prolonged HER2 blockade with trastuzumab.
- 21 January 2026
- Published by Alfmed LLC in Medical alphabet
- No. 33
HER2-positive metastatic gastric / cardioesophageal junction cancer: a comparative retrospective analysis of trastuzumab maintenance therapy regimens
Objective. To evaluate the efficacy and safety of different maintenance therapy regimens in patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Materials and methods. This retrospective analysis included data from 186 patients who received trastuzumab in combination with platinum-fluoropyrimidine chemotherapy. During the maintenance phase, patients were divided into two groups: trastuzumab monotherapy and trastuzumab plus fluoropyrimidines. Results. No significant differences were observed between the groups in overall survival (OS) or progression-free survival (PFS) (OS: 26.0 vs 24.0 months; PFS: 13.5 vs 13.1 months; p>0.05). Combination therapy was associated with a higher incidence of toxicity, including hand–foot syndrome (19.4 % vs 0.8 %) and cardiotoxicity (11.3 % vs 3.2 %). Conclusion. The continuation of fluoropyrimidines during the maintenance phase does not improve treatment efficacy and increases toxicity. The optimal strategy remains prolonged HER2 blockade with trastuzumab.
- Open Access
- 9 November 2025
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 34‑40
Prognostic factors in patients with colorectal cancer and isolated potentially resectable or unresectable liver metastases
Objective : to evaluate prognostic factors in patients with metastatic colorectal cancer (mCRC) and isolated liver metastases, and to analyze the role of systemic therapy in achieving resectability and the impact of surgical treatment on survival outcomes. Materials and methods . A retrospective study of 371 patients with mCRC and initially unresectable isolated liver metastases. Resectability was assessed by a multidisciplinary tumor board. Patients received systemic chemotherapy with targeted agents (bevacizumab or anti-EGFR). Progression-free survival (PFS), conversion rates, and prognostic factors were analyzed using univariate and multivariate methods. Results . The conversion rate to resectability was 60.1 % (potentially resectable metastases) and 25.9 % (unresectable metastases). Median PFS was 11.3 months (12.7 months for resectable vs. 10.5 months for unresectable). R 0 resection was achieved in 78.8 % and 72.4 % of patients, respectively. Multivariate analysis identified favorable prognostic factors: primary tumor resection and disease stabilization/partial response to therapy. Poor prognostic factors included unresectable metastases and limited/non-countable metastatic lesions. Conclusions . A combined systemic and surgical approach improves survival in mCRC patients, particularly after successful conversion of initially unresectable metastases.
- 9 November 2025
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 34‑40
Open AccessPrognostic factors in patients with colorectal cancer and isolated potentially resectable or unresectable liver metastases
Objective : to evaluate prognostic factors in patients with metastatic colorectal cancer (mCRC) and isolated liver metastases, and to analyze the role of systemic therapy in achieving resectability and the impact of surgical treatment on survival outcomes. Materials and methods . A retrospective study of 371 patients with mCRC and initially unresectable isolated liver metastases. Resectability was assessed by a multidisciplinary tumor board. Patients received systemic chemotherapy with targeted agents (bevacizumab or anti-EGFR). Progression-free survival (PFS), conversion rates, and prognostic factors were analyzed using univariate and multivariate methods. Results . The conversion rate to resectability was 60.1 % (potentially resectable metastases) and 25.9 % (unresectable metastases). Median PFS was 11.3 months (12.7 months for resectable vs. 10.5 months for unresectable). R 0 resection was achieved in 78.8 % and 72.4 % of patients, respectively. Multivariate analysis identified favorable prognostic factors: primary tumor resection and disease stabilization/partial response to therapy. Poor prognostic factors included unresectable metastases and limited/non-countable metastatic lesions. Conclusions . A combined systemic and surgical approach improves survival in mCRC patients, particularly after successful conversion of initially unresectable metastases.
- Open Access
- 19 June 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (2) , 41-51
Analysis of prognosis factors in patients with metastatic HER2‑positive gastric/cardioesophageal transition cancer treated in oncological clinics of Moscow
Introduction. Cancer of the stomach and cardio-esophageal transition is one of the key causes of mortality from malignant neoplasms in the world. Despite advances in targeted therapy in the treatment of HER2-positive gastric adenocarcinoma, the prognosis for most patients remains poor. The high degree of heterogeneity of the disease, relapse rates and limited treatment efficacy highlight the need to examine factors influencing therapy outcomes and possibility of their accounting in order to perform a personalized treatment.Aim. To evaluate the factors influencing progression-free survival and overall survival in patients with metastatic HER2-positive gastric cancer and/or cardio-esophageal transition.Materials and methods. The study included data from patients with metastatic HER2- positive gastric cancer from 5 oncology hospitals who received 1st-line trastuzumab between 2019 and 2024. Statistical analysis was performed using univariate and multivariate analyses to assess the impact of different clinical characteristics on progression-free survival and overall survival.Results. The study included 117 patients with metastatic gastric cancer who received trastuzumab in the 1st line of therapy. In univariate analysis of patient characteristics, the presence of bone metastases, age over 65 years, presence of ascites, ECOG status 1–2, degree of G3 differentiation, female sex were prognostically significant for progression-free survival and overall survival. As a result of multivariate analysis, age 65 years and older (p = 0.016), female sex (p = 0.003), presence of poorly differentiated tumors (p = 0.021), the presence of metastases in supraclavicular lymph nodes (p = 0.043) were prognosis factors associated with decreased overall survival. And the presence of secondary foci in bones was an independent prognosis factor associated with decrease in PFS according to results of multifactorial analysis (p = 0.043).Conclusion. Despite the effectiveness of targeted therapies, factors such as age, sex, functional status and metastasis localization have a decisive impact on the disease prognosis. Analysis of larger sample of patients is needed to definitively confirm the findings.
- 19 June 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (2) , 41-51
Open AccessAnalysis of prognosis factors in patients with metastatic HER2‑positive gastric/cardioesophageal transition cancer treated in oncological clinics of Moscow
Introduction. Cancer of the stomach and cardio-esophageal transition is one of the key causes of mortality from malignant neoplasms in the world. Despite advances in targeted therapy in the treatment of HER2-positive gastric adenocarcinoma, the prognosis for most patients remains poor. The high degree of heterogeneity of the disease, relapse rates and limited treatment efficacy highlight the need to examine factors influencing therapy outcomes and possibility of their accounting in order to perform a personalized treatment.Aim. To evaluate the factors influencing progression-free survival and overall survival in patients with metastatic HER2-positive gastric cancer and/or cardio-esophageal transition.Materials and methods. The study included data from patients with metastatic HER2- positive gastric cancer from 5 oncology hospitals who received 1st-line trastuzumab between 2019 and 2024. Statistical analysis was performed using univariate and multivariate analyses to assess the impact of different clinical characteristics on progression-free survival and overall survival.Results. The study included 117 patients with metastatic gastric cancer who received trastuzumab in the 1st line of therapy. In univariate analysis of patient characteristics, the presence of bone metastases, age over 65 years, presence of ascites, ECOG status 1–2, degree of G3 differentiation, female sex were prognostically significant for progression-free survival and overall survival. As a result of multivariate analysis, age 65 years and older (p = 0.016), female sex (p = 0.003), presence of poorly differentiated tumors (p = 0.021), the presence of metastases in supraclavicular lymph nodes (p = 0.043) were prognosis factors associated with decreased overall survival. And the presence of secondary foci in bones was an independent prognosis factor associated with decrease in PFS according to results of multifactorial analysis (p = 0.043).Conclusion. Despite the effectiveness of targeted therapies, factors such as age, sex, functional status and metastasis localization have a decisive impact on the disease prognosis. Analysis of larger sample of patients is needed to definitively confirm the findings.
- Open Access
- 15 April 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (1) , 76-85
Russian consensus on prevention, diagnosis and treatment of gastric cancer. Systemic therapy issues
The Russian consensus on prevention, diagnostic and treatment of gastric cancer was prepared on the initiative of the Moscow clinical scientific center named after A. S. Loginov on the Delphi method. Its aim was to clarify and consolidate the opinions of specialists on the most relevant issues of prevention, diagnosis and treatment of gastric cancer. An interdisciplinary approach was provided by the participation of leading gastroenterologists, oncologists and surgeons.
- 15 April 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (1) , 76-85
Open AccessRussian consensus on prevention, diagnosis and treatment of gastric cancer. Systemic therapy issues
The Russian consensus on prevention, diagnostic and treatment of gastric cancer was prepared on the initiative of the Moscow clinical scientific center named after A. S. Loginov on the Delphi method. Its aim was to clarify and consolidate the opinions of specialists on the most relevant issues of prevention, diagnosis and treatment of gastric cancer. An interdisciplinary approach was provided by the participation of leading gastroenterologists, oncologists and surgeons.
- Open Access
- 27 March 2025
- Published by Open Exploration Publishing
- Vol. 4, 100568
Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
Aim: Selecting patients for immunotherapy in metastatic gastric cancer (mGC) in second and subsequent lines remains challenging. The aim of our study is to assess the feasibility of anti-programmed death-ligand 1 (anti-PD-L1) inhibitors in pretreated patients with mGC, and to determine prognostic and predictive biomarkers. Methods: We retrospectively analyzed data of 122 patients treated in five oncology centers in Moscow between 2018 and 2023, who received nivolumab or pembrolizumab for advanced gastric cancer. The primary end-point of our study was 6-month progression-free survival (PFS). For multivariate analysis, variables with a value of p < 0.05 obtained in a univariate analysis were selected. The optimal threshold value of the neutrophil-lymphocyte ratio (NLR) as a predictor of the effectiveness of immunotherapy was determined using receiver operating characteristic (ROC) curve analysis. Results: Patients with mGC who received immune checkpoint inhibitors (ICIs) were included. 6-month PFS rate was 31.6%. The median PFS (mPFS) and overall survival (mOS) in patients in the high NLR group (NLR ≥ 1.8) were 2 and 4 months; mOS and mPFS in the low NLR group were not achieved (p < 0.001). The presence of ascites (p < 0.001), the administration of ICIs in III–IV lines (p = 0.004), and NLR ≥ 1.8 (p = 0.006) were independent prognostic factors, associated with decrease of OS. The median OS of patients in favorable and unfavorable prognostic groups were 13 months and 2 months, respectively (p < 0.001). Conclusions: Ascites, NLR level of ≥ 1.8, and administration of anti-PD-L1 inhibitors were associated with low efficacy of immunotherapy in patients with microsatellite stable mGC. Further research should be planned including patients who did not receive ICIs to determine the prognostic significance of our model.
- 27 March 2025
- Published by Open Exploration Publishing
- Vol. 4, 100568
Open AccessImmune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
Aim: Selecting patients for immunotherapy in metastatic gastric cancer (mGC) in second and subsequent lines remains challenging. The aim of our study is to assess the feasibility of anti-programmed death-ligand 1 (anti-PD-L1) inhibitors in pretreated patients with mGC, and to determine prognostic and predictive biomarkers. Methods: We retrospectively analyzed data of 122 patients treated in five oncology centers in Moscow between 2018 and 2023, who received nivolumab or pembrolizumab for advanced gastric cancer. The primary end-point of our study was 6-month progression-free survival (PFS). For multivariate analysis, variables with a value of p < 0.05 obtained in a univariate analysis were selected. The optimal threshold value of the neutrophil-lymphocyte ratio (NLR) as a predictor of the effectiveness of immunotherapy was determined using receiver operating characteristic (ROC) curve analysis. Results: Patients with mGC who received immune checkpoint inhibitors (ICIs) were included. 6-month PFS rate was 31.6%. The median PFS (mPFS) and overall survival (mOS) in patients in the high NLR group (NLR ≥ 1.8) were 2 and 4 months; mOS and mPFS in the low NLR group were not achieved (p < 0.001). The presence of ascites (p < 0.001), the administration of ICIs in III–IV lines (p = 0.004), and NLR ≥ 1.8 (p = 0.006) were independent prognostic factors, associated with decrease of OS. The median OS of patients in favorable and unfavorable prognostic groups were 13 months and 2 months, respectively (p < 0.001). Conclusions: Ascites, NLR level of ≥ 1.8, and administration of anti-PD-L1 inhibitors were associated with low efficacy of immunotherapy in patients with microsatellite stable mGC. Further research should be planned including patients who did not receive ICIs to determine the prognostic significance of our model.
- 8 September 2024
- Published by Alfmed LLC in Medical alphabet
- No. 17,p. 42-48
Interim results of a prospective randomised single-centre phase III study comparing mFOLFIRINOX and mFOLFOX6 regimens in the first-line treatment of HER2-negative gastric adenocarcinoma
Given the poor treatment outcomes of disseminated gastric cancer (dGC), the search for new drug treatment options remains a pressing issue. According to some literature, the use of a chemotherapeutic triplet in the first line improves patient survival rates. An interim analysis of a prospective randomised phase III trial examines the comparison of the chemotherapeutic regimens mFOLFIRINOX and mFOLFOX6 in the first-line treatment of HER2-negative gastric adenocarcinoma. In this interim analysis, significant differences between patients receiving mFOLFIRINOX or mFOLFOX6 regarding the primary endpoint of mVBP were detected only in the group of patients with dissemination to the retroperitoneal lymph nodes. Overall, based on the results of this work, it can be concluded that the majority of patients do not require intensification of first-line treatment for gastric adenocarcinoma in the form of mFOLFIRINOX chemotherapy. However, final conclusions on the efficacy of the triple combination can only be drawn upon completion of the entire study.
- 8 September 2024
- Published by Alfmed LLC in Medical alphabet
- No. 17,p. 42-48
Interim results of a prospective randomised single-centre phase III study comparing mFOLFIRINOX and mFOLFOX6 regimens in the first-line treatment of HER2-negative gastric adenocarcinoma
Given the poor treatment outcomes of disseminated gastric cancer (dGC), the search for new drug treatment options remains a pressing issue. According to some literature, the use of a chemotherapeutic triplet in the first line improves patient survival rates. An interim analysis of a prospective randomised phase III trial examines the comparison of the chemotherapeutic regimens mFOLFIRINOX and mFOLFOX6 in the first-line treatment of HER2-negative gastric adenocarcinoma. In this interim analysis, significant differences between patients receiving mFOLFIRINOX or mFOLFOX6 regarding the primary endpoint of mVBP were detected only in the group of patients with dissemination to the retroperitoneal lymph nodes. Overall, based on the results of this work, it can be concluded that the majority of patients do not require intensification of first-line treatment for gastric adenocarcinoma in the form of mFOLFIRINOX chemotherapy. However, final conclusions on the efficacy of the triple combination can only be drawn upon completion of the entire study.
- Open Access
- 24 May 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 9-18
Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study
Background: Due to the low efficacy of PD-L1 antibodies in second and subsequent lines of metastatic gastric cancer (mGC), the optimal treatment strategy of such patients and appropriate choice of predictive biomarkers remain challenging. The aim of our study is to assess the efficacy of immune checkpoint inhibitors monotherapy in patients with mGC in routine clinical practice, especially in heavily-pretreated patients. Materials and methods: We retrospectively analyzed data of patients treated in five oncology centers in Moscow between 2018 and 2023, who received nivolumab or pembrolizumab for advanced gastric cancer. Primary end-point of our study was 6-months PFS. Secondary end-points were overall survival (OS), objective respons e rate (ORR), and disease control rate (DCR). Toxicity was assessed using CTC AE v5.0 scale. Results: 122 patients with mGC who received immune checkpoint inhibitors were included between 1 January 2018 and 28 February 2023. 6-months PFS rate was 31,6 %. The median OS was 7 months (95 % CI: 2–20), the median PFS was 3 months (95 % CI: 1,5–9,5). A statistically significant difference in OS was detected in patients with MSI compared to MSS (25 months vs 6 months; 95 % CI: 0,21–0,86; HR: 0,43). A trend towards higher PFS was observed as well (10 months in MSI vs 3 months in MSS; 95 % CI:0,26–1,01; HR: 0,51). No statistical significance in PFS and OS according to PD-L1 CPS was found among patients with MSS. ORR and DCR were 36,6 % and 10,6 %, respectively. No cases of pseudoprogression or fatal immune-related AEs were observed. Conclusion: Our real-world data is consistent with published literature and the results from clinical trials. Further studies are needed to determine prognostic factors and to establish prognostic model of patients receiving ICIs for optimal treatment strategy of mGC.
- 24 May 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 9-18
Open AccessEfficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study
Background: Due to the low efficacy of PD-L1 antibodies in second and subsequent lines of metastatic gastric cancer (mGC), the optimal treatment strategy of such patients and appropriate choice of predictive biomarkers remain challenging. The aim of our study is to assess the efficacy of immune checkpoint inhibitors monotherapy in patients with mGC in routine clinical practice, especially in heavily-pretreated patients. Materials and methods: We retrospectively analyzed data of patients treated in five oncology centers in Moscow between 2018 and 2023, who received nivolumab or pembrolizumab for advanced gastric cancer. Primary end-point of our study was 6-months PFS. Secondary end-points were overall survival (OS), objective respons e rate (ORR), and disease control rate (DCR). Toxicity was assessed using CTC AE v5.0 scale. Results: 122 patients with mGC who received immune checkpoint inhibitors were included between 1 January 2018 and 28 February 2023. 6-months PFS rate was 31,6 %. The median OS was 7 months (95 % CI: 2–20), the median PFS was 3 months (95 % CI: 1,5–9,5). A statistically significant difference in OS was detected in patients with MSI compared to MSS (25 months vs 6 months; 95 % CI: 0,21–0,86; HR: 0,43). A trend towards higher PFS was observed as well (10 months in MSI vs 3 months in MSS; 95 % CI:0,26–1,01; HR: 0,51). No statistical significance in PFS and OS according to PD-L1 CPS was found among patients with MSS. ORR and DCR were 36,6 % and 10,6 %, respectively. No cases of pseudoprogression or fatal immune-related AEs were observed. Conclusion: Our real-world data is consistent with published literature and the results from clinical trials. Further studies are needed to determine prognostic factors and to establish prognostic model of patients receiving ICIs for optimal treatment strategy of mGC.
- Open Access
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 99-106
A clinical case of signet ring cell carcinoma of stomach in a child. Endoscopic diagnostics
Malignant neoplasms (MNP) of the gastrointestinal tract in children are extremely rare and account for 1.2 % of all MNP. According to world literature, the incidence of gastric cancer is no more than 0.05 % of all cases of MNP of the gastrointestinal tract in children. In national and foreign literature, only isolated cases of stomach cancer in children and adolescents aged 10 to 18 years are described. Clinical manifestations of the disease, as in patients over the age of 18, are non-specific – epigastric pain, loss of appetite, weight loss, ascites, anemia, melena and others. In this regard, the diagnosis occurs at the late stages of the disease and, therefore, is characterized by an unfavorable prognosis. Gastric signet ring cell carcinoma (SRCC) is an uncommon histologic subtype of adenocarcinoma and usually occurs in people aged 20 to 40 years. We would like to report an extremely rare case of SRCC in a 14-year-old child.
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 99-106
Open AccessA clinical case of signet ring cell carcinoma of stomach in a child. Endoscopic diagnostics
Malignant neoplasms (MNP) of the gastrointestinal tract in children are extremely rare and account for 1.2 % of all MNP. According to world literature, the incidence of gastric cancer is no more than 0.05 % of all cases of MNP of the gastrointestinal tract in children. In national and foreign literature, only isolated cases of stomach cancer in children and adolescents aged 10 to 18 years are described. Clinical manifestations of the disease, as in patients over the age of 18, are non-specific – epigastric pain, loss of appetite, weight loss, ascites, anemia, melena and others. In this regard, the diagnosis occurs at the late stages of the disease and, therefore, is characterized by an unfavorable prognosis. Gastric signet ring cell carcinoma (SRCC) is an uncommon histologic subtype of adenocarcinoma and usually occurs in people aged 20 to 40 years. We would like to report an extremely rare case of SRCC in a 14-year-old child.